Insulin-sensitisers in the treatment of polycystic ovary syndrome
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Polycystic ovary syndrome (PCOS) is a common endocrine condition with reproductive and metabolic implications. In the current setting there is an evolving, yet inadequate, understanding of the pathophysiology, long-term health implications and ideal therapies for women with PCOS. Insulin resistance, secondary to both genetic and lifestyle factors, is integrally involved in the pathogenesis, the metabolic and clinical features and the long-term sequelae of PCOS in a majority of patients. Therapeutic strategies targeting insulin resistance ameliorate clinical features and may reduce long-term sequelae of PCOS, including diabetes. The main benefit of improved insulin resistance is to improve fertility and potentially to improve clinical features of hyperandrogenism and lower androgen levels. Insulin sensitisers also have the potential to delay the development of diabetes and cardiovascular disease in PCOS. Lifestyle therapy is indicated as the first intervention; however, metformin as an insulin sensitising agent has a role in first-line medical therapy in women with PCOS. Further research is needed to define the role of insulin sensitisers in PCOS and to determine the long-term risks and benefits of these therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Katz, A., Nambi, S. S., Mather, K., Baron, A. D., Follmann, D. A., Sullivan, G., & Quon, M. J. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.7.6661 · Cited by 3,931 · cited 1×
“The euglycaemic hyperinsulinaemic clamp, considered the gold standard [54,55], is inappropriate for large interventional trials, primarily as it has poor reproducibility.”
BackgroundObesity, Fat Distribution, and Weight Gain as Risk Factors for Clinical Diabetes in Men
Chan, J. M., Rimm, E. B., Colditz, G. A., Stampfer, M. J., & Willett, W. C. (1994) · Diabetes Care · doi:10.2337/diacare.17.9.961 · Cited by 1,808
Legro, R. S. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.1.165 · Cited by 1,743
Wild, S., Pierpoint, T., McKeigue, P., & Jacobs, H. (2000) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2000.01000.x · Cited by 970
Velazquez, E. M., Mendoza, S., Hamer, T., Sosa, F., & Glueck, C. J. (1994) · Metabolism · doi:10.1016/0026-0495(94)90209-7 · Cited by 865 · cited 1×
“Metformin, given its beneficial effects on IR, was first reported in PCOS in 1994 [20].”
BackgroundNestler, J. E., & Jakubowicz, D. J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608293350902 · Cited by 743
Pasquali, R., Gambineri, A., Biscotti, D., Vicennati, V., Gagliardi, L., Colitta, D., Fiorini, S., Cognigni, G. E., Filicori, M., & Morselli-Labate, A. M. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.8.6738 · Cited by 635 · cited 4×
“Reductions in BMI and WHR with metformin have been reported [13,33,37], primarily attributed to appetite suppression.”
BackgroundResultInfluentialPhillips, D. I. W., Clark, P. M., Hales, C. N., & Osmond, C. (1994) · Diabetic Medicine · doi:10.1111/j.1464-5491.1994.tb00273.x · Cited by 631 · cited 1×
“Alternative measures, including fasting insulin levels, the homeostasis model assessment (HOMA), the quantitative insulin sensitivity check index and the OGTT with calculations of IR, have been validated in non-diabetic populations [56-58].”
MethodMoran, L. J., Noakes, M., Clifton, P. M., Tomlinson, L., & Norman, R. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020815 · Cited by 530
Self-citation
Cited by
Rachoń, D., & Teede, H. (2010) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2009.09.026 · Cited by 161
Self-citationMeyer, C., McGrath, B. P., & Teede, H. J. (2007) · Diabetes Care · doi:10.2337/dc06-0618 · Cited by 148
Self-citationThe management of insulin resistance in polycystic ovary syndrome
Teede, H. J., Hutchison, S. K., & Zoungas, S. (2007) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2007.08.001 · Cited by 135
Self-citationMisso, M. L., Costello, M. F., Garrubba, M., Wong, J., Hart, R., Rombauts, L., Melder, A. M., Norman, R. J., & Teede, H. J. (2013) · Human Reproduction Update · doi:10.1093/humupd/dms036 · Cited by 81
Self-citationInsulin levels, insulin resistance and the use of metformin in polycystic ovary syndrome
Hutchison, S. K., Zoungas, S., & Teede, H. J. (2007) · Medical Journal of Australia · doi:10.5694/j.1326-5377.2007.tb00889.x · Cited by 4
Self-citation
Metadata
- Authors
- Teede, H. J., Meyer, C., & Norman, R.
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa Healthcare
- Published
- 2005-10-31
- Volume
- 6
- Issue
- 14
- Pages
- 2419-2427
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W2084487206
- Cited by
- 18
- References
- 19
- FWCI
- 3.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Insulin-sensitisers in the treatment of polycystic ovary syndrome. https://app.cochat.ai/papers/10.1517/14656566.6.14.2419
- The paper
- Teede, H. J., Meyer, C., & Norman, R. (2005). Insulin-sensitisers in the treatment of polycystic ovary syndrome. Expert Opinion on Pharmacotherapy. https://doi.org/10.1517/14656566.6.14.2419
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.